Autopsy report · NCT04348916
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Cause of deathFunding or business
“Terminated due to Oncorus portfolio reprioritization”
Life of this trial
- Registered 1 month before it started.
- Ran for about 3 years before it stopped.
- 66 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Oncorus, Inc.
- Sponsor type
- Industry
- Conditions
- Cancer; Melanoma; Solid Tumor; Squamous Cell Carcinoma of Head and Neck; Breast Cancer; Advanced Solid Tumor
- Interventions
- ONCR-177; pembrolizumab
- Participants
- 66
- Sites
- 11
- Countries
- Canada, United States
Trials that died the same way
- A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
“This study was terminated as a result of Sponsor portfolio reprioritization.” - A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
“termination due to portfolio prioritization” - Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
“Terminated due to low accrual.” - A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
“Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.